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Abstract
Microsatellite instability (MSI) and loss of heterozygosity (LOH) represent molecular disorders acquired by the cell during neoplastic 
transformation. Both are associated with genetic instability. Functional silencing of tumour suppressor genes may be the consequence of 
genomic instability, particularly of the globally occurring LOH phenomenon. Numerous studies have confirmed the role of MSI/LOH 
at both the early and the late stages of thyroid tumourigenesis. This paper reviews the available study results on MSI/LOH significance 
and prevalence in thyroid neoplasms. Additionally, it summarises the knowledge regarding the practical usage of the study findings on 
MSI/LOH in aspects of cancer risk assessment as well as the development of prognostic markers for thyroid neoplasms. 
(Pol J Endocrinol 2012; 63 (2): 126–136)
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Streszczenie
Niestabilność mikrosatelitarna (MSI) i utrata heterozygotyczności (LOH) to zaburzenia molekularne, które w znacznym stopniu wiążą 
się z nabywaniem przez komórkę nowotworową niestabilności genetycznej. Funkcjonalną konsekwencją niestabilności w genomie 
— a w szczególności globalnie występującego LOH — może być utrata funkcji genów supresorowych. Przeprowadzone liczne badania 
procesu nowotworzenia w gruczole tarczowym potwierdziły rolę MSI/LOH zarówno we wczesnych, jak i poźnych stadiach karcynogenezy. 
W pracy przedstawiono wyniki badań dotyczących znaczenia i częstości występowania MSI/LOH w procesie nowotworzenia w gruczole 
tarczowym. Artykuł jest także podsumowaniem stanu wiedzy na temat praktycznego wykorzystania rezultatów badań dotyczących 
MSI/LOH w ocenie ryzyka wystąpienia nowotworu i w opracowaniu markerów prognostycznych przebiegu choroby nowotworowej 
tarczycy. (Endokrynol Pol 2012; 63 (2): 126–136)
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Introduction
Thyroid cancer accounts for the majority of endocrine 
malignancy in the world, and its incidence is still in-
creasing [1]. Follicular cell-derived thyroid carcinoma 
includes several morphological types: (1) well-dif-
ferentiated thyroid carcinoma (WDTC), (2) poorly 
differentiated thyroid carcinoma (PDTC), and (3) 
undifferentiated (anaplastic) thyroid carcinoma (UTC; 
ATC) [2–4]. These types are phenotypically distinct, 
revealing different potential degrees of malignancy, 
from relatively indolent (as PTC, papillary thyroid 
carcinoma, belonging to WDTC) to highly aggressive 
tumours (UTC) with a poor prognosis. PDTCs displays 
intermediate biological and clinical features, and show 
a high tendency towards recurrence of symptoms, me-
tastasis and progressive dedifferentiation of follicular 
cells [3, 5–7]. ATC is characterised by dynamic growth, 
local infiltration and multiple distinct metastases, as 
well as high lethality [8, 9].
In the WDTC group, about 90% of newly diagnosed 
cases represent PTC, and about 10% represent follicular 
thyroid carcinoma (FTC) [10]. FTC is the more aggres-
sive tumour, with a poorer prognosis than PTC, display-
ing more rapid growth, local infiltration and higher rate 
of distinct metastases [11].
According to classic carcinogenesis theory, the de-
velopment of a tumour derived from well-differentiated 
cells is associated with dedifferentiation, uncontrolled 
proliferation and loss of apoptosis ability. There are 
clinical, epidemiologic, and genetic evidences support-
ing the hypothesis of gradual progression and dedif-
ferentiation of thyroid cancer derived from follicular 
thyroid cells [12, 13].
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Although understanding of the possible molecular 
mechanisms underlying this process is still insufficient, 
there have been several studies assessing the molecular 
factors that may play an essential role in the dediffer-
entiation of WDTC [13–15].
It is believed that one of these factors is genetic 
instability. This term refers to an accumulation of chro-
mosomal aberrations and/or genetic mutations in cells 
undergoing neoplastic transformation [16–18].
Microsatellite sequences and MSI/LOH
Microsatellite sequences consist of long, tandem repeats 
of between one and six nucleotides. The number of 
nucleotide repeats varies, ranging, on average, from 
five to 100 segments, with a total length of repetitive 
DNA of 100–600 bp [19]. In the human genome, it has 
been demonstrated that the cytosine/adenine (CA)n 
sequence is a repetitive unit of the highest prevalence, 
being spread throughout thousands of locations [19–20]. 
Microsatellite sequences are found in all chromosomes, 
with an average density of about 14.000 bp/Mbp [21].
The changes in lengths of microsatellite sequences, 
for which the mutation rate is higher than in other 
regions of the genome, are the basis of genetic insta-
bility [18]. Microsatellite instability (MSI), defined as 
the occurrence of an allele of a new, and thus never 
observed, length, is one of the mechanisms associated 
with genetic instability [16]. The major contributor to 
microsatellite mutagenesis is DNA polymerase slip-
page during replication. It results in errors within 
microsatellites with a frequency 10- to 100-fold higher 
than the frequency of frameshifts in coding sequences 
[18, 20]. This process leads either to DNA transcript 
elongation or its shortening, depending whether 
wrongly paired base pairs are localised on a template 
strand or a daughter strand. Additionally, the loss of 
function of the DNA mismatch repair (MMR) genes, 
mainly of MLH1, MSH2, MSH6, the mutations in 
which are confirmed in a high percentage of neo-
plasms, is also the cause of microsatellite instability, 
manifested by constant and irreversible molecular 
changes [22]. The molecular mechanism of MSI is 
shown in Figure 1.
Loss of heterozygosity (LOH) is a phenomenon 
contrary to MSI. In this genetic disorder, one of 
the gene alleles is lost in a neoplastic cell [16]. The 
mechanism of LOH is chromosome-specific, and it 
Figure 1. Mechanism of microsatellite instability (MSI) formation. Modified on [20]. (1) DNA replication. (2) CA repeat, wrongly 
incorporated into the chain of replicated DNA. (3a) Maintained microsatellite stability (MSS) by an effective MMR system. (3b) MMR 
system defect: lack of elimination of wrongly incorporated into DNA nucleotides and resulting MSI
Rycina 1. Mechanizm powstawania niestabilności mikrosatelitarnej (MSI). Zmodyfikowano na podstawie [20]. (1) Replikacja DNA. 
(2) Błędnie wbudowane powtórzenie CA w łańcuch replikowanego DNA. (3a) Zachowanie stabilności sekwencji mikrosatelitarnych 
(MSS) poprzez działanie sprawnego systemu MMR. (3b) Defekt MMR; brak usuwania błędnie wstawionych nukleotydów w czasie 
replikacji DNA, powstanie MSI
128
MSI and LOH in the development and prognosis of follicular cell-derived thyroid tumours Monika Migdalska-Sęk et al.
PR
A
C
E 
PO
G
LĄ
D
O
W
E
may concern the entire chromosome. However, loss 
of genetic material is more often associated with dele-
tion of a fragment of chromosome, leading to LOH 
regarded as a generalised form of allelic imbalance. 
Loss of function of suppressor as well as mutator 
genes may be a functional consequence of the glo-
bally occurring LOH [17]. According to the “two hit” 
hypothesis postulated by Knudson [23], loss of func-
tion of both tumour suppressor gene (TSG) copies is 
required for an uncontrolled proliferation of modified 
cells and, eventally, for neoplastic transformation. In 
the classical mechanism of TSG inactivation, one allele 
is inactivated either by promoter hypermethylation 
or point mutation (e.g. substitution) or intragenic 
microdeletion, while the second allele is lost via LOH 
[17, 23]. Figure 2 shows genetic changes leading to 
silencing of suppressor gene functions in neoplastic 
transformation.
In MSI/LOH analysis, highly polymorphic microsat-
ellite loci, called microsatellite markers, are used. These 
studies compare the changes in the length of microsatel-
lite alleles between DNA isolated from neoplastic tissue 
and DNA from macroscopically unchanged tissue (con-
trol) of the same patient. The MSI/LOH phenomenon 
can be identified only when it simultaneously occurs 
in many tissues.
Then, it may serve as an indicator of the clonal ex-
pansion of cells, typical for a given neoplasm [20]. MSI 
is the basis of the so-called replication error phenotype 
(RER), and the neoplasms with confirmed microsatellite 
instability are classified as RER+ [16]. In turn, studies 
on LOH, using cytogenetics and molecular biology 
techniques, can identify the minimally deleted regions 
(MDR) in chromosomes. In neoplastic cells, loss of 
genetic material in MDR indicates the presence of sup-
pressor or mutator genes [24, 25]. A practical use of the 
studies on MSI/LOH is associated with the possibility 
of neoplasm risk evaluation and with the development 
of informative diagnostic and predictive markers of the 
neoplastic disease course.
Figure 2. TSG inactivating genetic changes, following Knudson’s “two-hit” hypothesis. Modified on [17]. The first molecular event 
is the rare mutation in gene sequence (microdeletion or substitution), which — transferred in the germinal line — can become a cause 
of hereditary cancer. The second molecular event, LOH, is a mechanism frequently observed in somatic cells, leading to either hemi- 
or homozygosity of the chromosomal region via: (a) nondisjunction with reduplication of mutated TSG containing chromosome, 
(b) subchromosomal deletions, (c) imbalanced translocations, (d, e), miotic recombinations
Rycina 2. Genetyczne zmiany inaktywujące TSGs według teorii „dwóch zdarzeń” Knudsona. Zmodyfikowano na podstawie [17]. Pierwszym 
zdarzeniem molekularnym jest rzadka mutacja w sekwencji DNA genu (mikrodelecja lub substytucja), która może być przekazywana w linii 
germinalnej i może stać się przyczyną dziedzicznej formy raka. Drugie zdarzenie molekularne — LOH — jest częstym mechanizmem 
w komórkach somatycznych, prowadzącym do hemi- lub homozygotyczności regionu chromosomu na drodze: (a) nondysjunkcji 
z reduplikacją chromosomu zawierającego zmutowany TSG, (b) subchromosomalnych delecji, (c) niezrównoważonych translokacji, 
(d, e), miotycznych rekombinacji
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MSI in thyroid carcinogenesis
There have been few reports concerning the participa-
tion of microsatellite instability in the neoplastic trans-
formation of thyroid follicular cells. The first study 
— with the use of three microsatellite markers (D2S123, 
D2S119, D2S147) localised on chromosome 2 and includ-
ing the MSH2 locus — did not confirm MSI participation 
in the process of neoplasia in the thyroid gland [26].
However, later studies provided evidence for the 
presence of microsatellite instability both in benign 
and malignant lesions of the gland. They also proved 
a different incidence (0–25%) of MSI between the 
histopathological types of thyroid neoplasm [27–31]. 
Out of the various types of neoplastic thyroid le-
sions (PDTC, FTC, PTC, FA), the lowest percentage 
of samples with MSI within at least one locus was 
observed in poorly differentiated thyroid carcinomas 
[27]. Thus, microsatellite instability does not seem to 
play any key role in PDTC progression. MSI seems to 
play a rather limited role in the development of papil-
lary thyroid carcinoma, for which, the percentage of 
samples with microsatellite instability is 7–17% [27–29, 
31–33]. Moreover, the studies employing the Bethesda 
panel did not prove any significant role of MSI in the 
aetiopathogenesis of PTC, while emphasising the lack 
of relationship between MSI and mutations of repair 
genes, MLH1 and MSH2 [34].
A slightly higher incidence of microsatellite instabil-
ity in at least one locus is observed in follicular thyroid 
carcinoma (8–25%) [27, 31]. There are indeed reports 
which indicate a close relationship between MSI in 
a given microsatellite locus (D2S123) on chromosome 
2 (2p16.3) and FTC phenotype [35, 36]. These reports 
confirmed MSI in 100% of the studied FTC samples 
within the D2S123 locus.
Additionally, microsatellite instability in the D2S123 
locus, demonstrated also in follicular adenomas (FAs), 
may support the view on MSI role in neoplastic trans-
formation of the thyroid gland [35, 36].
It is worth noting that MSI has been observed 
not only in DNA from either FA or FTC, but also in 
preneoplastic lesions (i.e. in nodular goitre — NG or 
hyperplastic goitre) [27, 30]. It must also be emphasised 
that MSI occurs more often in non-neoplastic tissue 
than in either PTC or FTC [37]. These results suggest 
that microsatellite instability is a molecular mechanism 
associated with an early stage of carcinogenesis in the 
thyroid gland. Figure 3 presents the incidence of mic-
rosatellite instability, observed in at least in one locus, in 
selected lesions of the thyroid gland, according to the 
results of different studies.
It is also significant that, of all the studied thyroid 
neoplastic lesions characterised by MSI, 7–50% of tu-
mours demonstrate microsatellite instability in more 
than 30% of used microsatellite loci, which qualifies 
these cases to the RER+ phenotype [27, 28, 36]. How-
ever, because of the varying numbers of employed 
microsatellite loci, the different techniques used for MSI 
analysis, and varying group sizes, the results of these 
studies are somewhat controversial and difficult to 
compare. Additionally, a precise technique of selection 
of neoplastic cells plays a significant role in MSI analy-
sis. Such a method, employed to acquire and differenti-
ate neoplastic cells from the surrounding neoplastically 
unchanged cells, is laser capture microdissection (LCM). 
LCM has been used to prove a high incidence of 
malignant thyroid tumours (PTC — 64.2% and FTC 
— 62.5%) characterised by microsatellite instability 
— high (MSI-H) phenotype [36]. Following the criteria 
of MSI classification in neoplasms, MSI-H tumours 
are classified if two out of five studied markers, or 
Figure 3. Prevalence of MSI (in at least one locus) in neoplastic and non-neoplastic thyroid tissue, according to literature data [27–31]
Rycina 3. Częstość występowania MSI (w co najmniej jednym locus) w tkance nowotworowej i nienowotworowej gruczołu tarczowego, 
na podstawie danych z piśmiennictwa [27–31]
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more than 30–40% (in cases where a higher number 
of loci is evaluated) demonstrate instability [16, 20, 22]. 
Moreover, using the LCM method, it was found that 
90% of FAs revealed microsatellite stability [36]. This 
suggests that the MSI status of cells can be a marker 
differentiating neoplastic lesions in the thyroid gland. 
Other reports, based on autoradiographic evaluation 
of electrophoretically separated PCR products, have 
confirmed an elevated incidence of MSI-H in follicular 
neoplasms (FA, FTC; 33%) as compared with PTC (3%) 
or Hurthle cell lesions (0%) [28]. These observations do 
not concur with the results obtained by Soares et al. [27], 
who observed MSI-H in 8% of studied PTCs, while not 
finding it in any FTC. 
To sum up, due to the rather small number of stud-
ies concerning microsatellite instability analysis in 
thyroid neoplasms, as well as differing methods and 
analysed loci and, finally, to the controversial results of 
the studies, MSI can neither be regarded as a marker 
differentiating benign lesions from malignant ones, nor 
as a marker differentiating particular histopathological 
types of neoplasms.
MSI prognostic values in thyroid cancers
Attempts have been made to answer the question as to 
whether MSI can be a useful prognostic marker of thy-
roid cancer. On the one hand, no statistically significant 
relationship has been observed between the status of 
MSI and the patient’s age at the time of disease diagnosis 
[36]; on the other hand, a correlation has been observed 
between the incidence of MSI and the advanced age of 
patients, when MSI analysis involved the loci of genes 
particularly important for thyroid functions [35].
Statistically significant differences in MSI incidence 
have been observed in the thyreotropin receptor (TSHR) 
gene locus in thyroid carcinoma in patients aged above 
70 and below 70 (50% and 14.7%, respectively). It has 
been found that elderly patients, characterised by 
a higher incidence of MSI, have a better prognosis, in-
dicating the usefulness of MSI as a prognostic tool [35].
The occurrence of MSI in the TSHR locus also demon-
strates its significance in the process of thyroid cancer 
metastasis. MSI in the TSHR locus was significantly more 
often observed in the group of patients with lymph 
nodes metastases more distant from the primary tumour 
(N3–4), compared to either a group of patients without 
metastases (N0) or those with N1–2 metastases [35].
While analysing the significance of MSI as a prog-
nostic factor for primary tumour size, it has been con-
firmed that thyroid tumours of size > 4 cm are more 
often characterised by stable microsatellites (MSS) 
[36]. The authors of this study suggested two differ-
ent types of malignant thyroid neoplasms. The first 
included tumours in size 4 cm, which — following the 
histopathological identification — were probably quali-
fied for immediate surgical removal; their status might 
have been that of MSI-H. The second type, i.e. tumours 
of size > 4 cm, previously submitted to observation 
and non-invasive prophylactic treatment, developed 
probably from benign precursor change (adenomas), 
and might have represented the status of MSS [36]. 
Therefore, it may well be assumed that, regarding the 
tumour progression from benign neoplastic to malig-
nant form, microsatellite instability is neither a key nor 
a sufficiently causative molecular event. However, it 
should be kept in mind that other genetic factors (e.g. 
mutations in RET, RAS, BRAF, MET or TP53), also par-
ticipate in the mutational pathway of thyroid neoplasms 
[38–42]. Additionally, beside mutations in the RET or 
TP53 genes, the presence of MSI in the  loci of both genes 
is very important for their inactivation. MSI in the RET 
locus has been observed in young (< 30) patients with 
PTC, who had in the past been exposed to radiation 
(i.e. the Chernobyl explosion) [43]. In turn, the presence 
of MSI in the TP53 locus [35] was associated with gene 
inactivation — regarded as the main genetic event in 
the dedifferentiation process of thyroid carcinoma cells 
towards ATC [44]. It is important that a high prevalence 
of MSI (36.5–45.9%) was also observed in the locus of 
triiodothyronine nuclear receptor (THRα1), exon 9 of 
which contains repetitive sequences of (CA)18.
However, no correlation has been observed between 
the presence of MSI in the locus of the gene with clinical 
features of the patients or with histopathological type 
of thyroid cancer [35, 36].
Survival data confirms a better prognosis for patients 
with thyroid neoplasms characterised by MSI than from 
thyroid neoplasms characterised by MSS phenotype 
[35]. This observation suggests the usefulness of MSI 
status as a prognostic factor.
LOH in thyroid carcinogenesis
The results of studies concerning the role of LOH in 
the process of neoplastic transformation of thyroid cells 
have demonstrated that inactivation of various genes by 
deletions in their loci is already present in preneoplastic 
lesions, being associated with the process of carcinogen-
esis initiation in the thyroid gland. However, the role of 
that phenomenon varies, depending on chromosomal 
region and the significance of the LOH-affected loci in 
the physiology of the thyroid gland.
LOH analysis in the TPO locus (2p24-25) — the key 
important gene in thyroid hormone synthesis — has 
revealed its presence in thyroid nodules. The lack 
of simultaneous somatic mutations in the gene sug-
gested the possibility of deletions within other genes 
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of that region, participating in the process of neoplas-
tic transformation [45]. Additionally, LOH has been 
demonstrated in colloid nodules of the thyroid gland 
and confirmed within the 10q22.2 locus [46]. Deletions 
of the 10q22-24 region have often been observed in 
thyroid follicular adenomas [46–49]. Moreover, studies 
performed in benign neoplasms, concerning different 
histopathological types, have demonstrated the high-
est percentage (75%) of LOH in 10q22-23 in atypical ad-
enomas vs. benign lesions originating from the Hurthle 
cells (Hurthle cell adenoma — HA) (11%), or typical 
follicular adenomas (13%) [48]. These results suggest 
not only the possibility of using LOH as a marker dif-
ferentiating histopathological subtypes of follicular 
adenoma; they also confirm the fact that FA progres-
sion from typical to atypical form may be associated 
with inactivation of TSGs in the 10q22-23 region [48]. 
It is known that this locus contains the PTEN gene, the 
dysfunction of which leads to uncontrolled cell prolif-
eration [50]. So, it can be assumed that LOH in this locus 
may be associated with the progression of an atypical 
adenoma into a malignant neoplasm. However, the 
results of the studies are far from unequivocal. Some 
reports describe more frequent LOH in the 10q22-24 re-
gion in FAs than in FTCs [46, 49], while others have 
reported the opposite: a much higher percentage of 
LOH in this region in FTCs (100%) vs. FAs (13%) [51]. 
Probably, a slow progression from the stage of benign 
into malignant lesion — beside PTEN inactivation 
— requires also dysfunction of other genes [49, 51].
Loss of heterozygosity in other chromosomal re-
gions, such as: 11p15.5, 6q24-q26 and 1p31.2 (83%, 50% 
and 60%; respectively) has also been more frequently 
found in atypical FAs vs. typical FAs. 
Based on the above-mentioned studies, it may be 
concluded that certain potential suppressor genes, playing 
a key role in neoplastic transformation in the thyroid gland, 
are localised in those regions. Regarding the 11p15 region, 
the following imprinted genes are postulated: CDKN1C, 
KCNQ1, IGF2, IGF2-AS, H19 and INS [52]. Understanding 
the mechanism of KCNQ1 inactivation seems to be par-
ticularly important, mainly for its participation in thyroid 
hormone synthesis control. It is known that the KCNQ1 
gene product plays a significant role, together with the 
sodium-iodide symporter (NIS), in iodide transport in the 
cellular membranes of thyrocytes [53, 54]. Moreover, it has 
already been proven that kcnq1 protein deficit disturbs cell 
proliferation in the thyroid gland [55].
Despite the fact that the development of thyroid 
follicular adenoma may have strong associations with 
LOH, both within the long arm of chromosome 10 (10q) 
and the short arm of chromosome 11 (11p), this does 
not exclude the involvement of other deletion regions 
(e.g. 1p13, 3p14-25, 7q21.1-q31.2, 11p, 11q23 or 17p13).
The prevalence of LOH in selected chromosomal 
regions in cases of thyroid follicular adenoma is shown 
in Figure 4. 
An interesting hypothesis as to the molecular 
sequence of genetic events in carcinogenesis in the 
thyroid gland was proposed by Sarquis et al. [52]. They 
suggested the role of the 15q11-q13 region, as a hot 
LOH site, associated with inactivation of IPW, UBE3A, 
ATP10 genes and leading to a neoplastic transformation 
of normal thyroid cells towards adenoma. In turn, the 
imprinted genes: ARHI (1p31.2), CDKN1C (11p15.5), 
IPW (15q11-12), SNRPN (15q11.2), SNURF and NDN 
(15q13.1), in case of which a decreased expression was 
observed in FTC as compared with FA, take part in 
Figure 4. Prevalence of LOH in various chromosomal regions in FA, according to literature data [31, 46, 47, 49, 56–58]
Rycina 4. Częstość występowania LOH w różnych regionach chromosomów w FA, na podstawie danych z piśmiennictwa [31, 46, 47, 
49, 56–58]
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differentiation of typical adenomas into an atypical form, 
thus confirming their role in the early stage of neoplastic 
transformation towards malignant lesion (FTC) [52].
Loss of heterozygosity in the 7q21.1-q31.2 region is 
also regarded as an early and probably initiating event 
in the development of follicular adenoma [46, 56–60]. 
The progressive character of the process is particularly 
evident for LOH in the 7q31.2 locus, which is assigned 
the role in FA transformation towards follicular thyroid 
carcinoma [46, 56, 57]. The high incidence of the loss 
of heterozygosity in FTC (50–55%) and lower in FA 
(22–27%) — confirmed for D7S480 and D7S490 mark-
ers, which flank the region — suggest that the 7q31.2 
locus could be the MDR, specific for FTC [56], similarly 
to the 7q21.2 (D7S492) region [60]. Moreover, the higher 
percentage of malignant tumours with LOH observed in 
those loci, vs. benign lesions may confirm the hypothesis 
that the development of FA and FTC is associated with 
a clonal event, occurring in a single precursor cell [56, 
60]. Most probably, LOH in the 7q region also predis-
poses FTC cells to undergo dedifferentiation towards 
anaplastic thyroid carcinoma (ATC) [46, 59–60].
It should be emphasised that in thyroid tumours (ATC, 
FTC and PTC), within which LOH was studied in 7q, as 
well as the expression levels of HGF (hepatocyte growth 
factor) and of its receptor, HGF-R (c-MET) (7q21, 7q31; re-
spectively), gene overexpression with a simultaneous lack 
of LOH was demonstrated in the PTC group only. Oppos-
ing results were obtained in FTC and ATC cases, where 
loss of expression and LOH presence were observed in 
the studied loci [59]. The results of that study suggest 
a certain usefulness of the microsatellite markers, localised 
in the 7q region, in differentiating FTCs vs. PTCs. They 
also reflect a genetic distinction of cells in these two types 
of thyroid neoplasm. Moreover, based on the above pre-
sented results, Trovato et al. [59] proposed a hypothesis 
regarding the localisation of other suppressors participating 
in the mutational pathway (FA Æ FTC Æ ATC), to be close to 
HGF and HGF-R genes. While it is true that a subsequent 
work by Trovato et al. [60] did not reveal any new genes 
within the 7q region which could play a significant role 
in neoplastic transformation of thyroid follicular cells, it 
did provide some important data, proving that LOH in 
the 7q21 locus is the key event in the FA Æ FTC Æ ATC 
mutational pathway. The observed mean fractional allelic 
loss (FAL) values were similar in goitres and hyperplastic 
lesions, while significantly increasing with neoplastic 
transformation, i.e. higher FAL values were calculated for 
FTC and ATC than for FA. The allelic loss at 7q21 – more 
frequent in FTC as compared with PTC — was found to be 
related to iodine-deficient geographical areas. Addition-
ally, Trovato et al. observed that the mean size of thyroid 
gland with LOH was increased by up to 10 cm. Therefore, 
it was claimed that LOH in thyroid glands predisposed 
to intense growth stimuli [60]. Other authors have sug-
gested that iodine deficiency influences MSI/LOH, and 
may serve as an indicator of defective MMR functions in 
thyroid tumourigenesis [61].
Beside the above-mentioned chromosome 7q — un-
dergoing a selective loss in FTC — deletions in other 
chromosomal loci have also been described as a causa-
tive factor of follicular thyroid carcinoma development. 
These concern the following regions: 1p34.2, 2p, 2q, 
11p13-15, 17p13 and 22q, in which, the mapped TSGs, 
e.g. L-MYC1 (1p34.2), WT1 (11p13), TP53 (17p13.1), NF2 
(22q12.2) or SNF5/INI1 (22q11.2) may be significant for 
FTC development [47, 51, 58, 62, 63]. In FTC, a high 
percentage of samples with LOH was observed, as much 
as 30-86%, depending on the studied chromosomal 
region (Figure 5).
Figure 5. Prevalence of LOH in FTC, in various chromosomal regions, according to literature data [31, 47, 56, 62–64]
Rycina 5. Częstość występowania LOH w różnych regionach chromosomów w FTC, na podstawie danych z piśmiennictwa [31, 47, 
56, 62–64]
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It also seems that a specific feature for FTC is LOH 
within the short arm of chromosome 3 (3p), where 
a few deletion regions are considered: 3p13-cen, 
3p14.2~p14.1, 3p21.1, 3p24-25 and 3p26.3 [31, 47, 64]. 
The obtained results are, however, controversial, as in 
the study conducted by Rodrigues-Serpa et al. [31], 
3p25.3~pter and 3p21.2-p12 regions were specific 
for FTC, while a relatively high prevalence of LOH 
in 3p25.3-p24.2 was confirmed in PTC development. 
In turn, other authors have pointed to 3p25~pter as 
a region of considerable loss of heterozygosity in PTC 
development [47]. The observations of LOH in the 3p 
region in FTC and FA become fairly interesting from 
the perspective of the possible identification of poten-
tial suppressor genes within this chromosomal region. 
Especially interesting given that their deletions may 
turn out to be helpful in improving the differential 
diagnostics of thyroid follicular neoplasms. LOH in the 
VHL locus (3p25.3), more frequently found in widely 
invasive FTC and angioinvasive HTC, turned out to 
be a molecular marker specific for these malignant 
neoplasms [65]. This fact was very significant regarding 
the function of VHL as a suppressor gene. It was proven 
that a loss of function of the gene was associated with 
disturbed control of cell survival, the progression of cell 
cycle, angiogenesis, cell migration and invasion [66].
An analysis of the loss of heterozygosity was also un-
dertaken in cases of papillary thyroid carcinoma. In that 
type of neoplasm, the presence of LOH was estimated 
to be 13–54%, depending on the studied chromosomal 
region (Figure 6).
The relatively high prevalence of LOH in 9p in PTC 
has prompted a search for potential genes localised in 
that particular chromosomal region. It is postulated that 
LOH in CDKN2A and CDKN2B genes (9p21) could be 
the main mechanism, inactivating these genes, recog-
nised as neoplastic suppressors and — probably — play-
ing an important role in PTC development [33, 68, 69]. 
It is not excluded that inactivation of other genes, such 
as: CMM (1p36.2), L-MYC1 (1p34.2), PTCH1 (9q22.1), 
TP53 (17p13) and NF2 (22q12.2), localised in the loci with 
confirmed LOH, take part in PTC development and 
progression [68, 70]. Recently, the participation of LOH 
in hOGG1 (major repair gene for free radical-induced 
oxidative DNA damages) locus in PTC development has 
been suggested. A high incidence of LOH in hOGG1 has 
been found in PTCs and also in Hashimoto’s thyroiditis 
(HTs), but not in benign goitres. This supports the hy-
pothesis that thyroid follicular epithelium accumulates 
aberrant genetic changes in long-standing HT, which 
might represent a precursor lesion of PTC [71].
Studies to date have emphasised the considerable 
differences in LOH prevalence between PTC and FTC 
[31, 47, 58, 59, 64]. These observations not only suggest 
a different molecular pathway of development of these 
main two thyroid carcinoma types, but they also indi-
cate their different biological features.
LOH prognostic value in thyroid cancers
There have been few reports regarding the prognostic 
significance of LOH in the thyroid gland. However, 
some researchers have pointed to progressive LOH 
incidence along with neoplastic transformation. The 
highest LOH incidence was observed for the more 
malignant carcinomas, such as HCC or FTC [60, 72]. For 
example, in the region of 17p13.1, loss of heterozygosity 
was more often associated with a higher stage of FTC 
development, as well as with its higher growth rate. 
Moreover, in that chromosomal area, a narrow mini-
Figure 6. Prevalence of LOH in PTC in various chromosomal regions, according to literature data [31–33, 46, 47, 57, 64, 67–69]
Rycina 6. Częstość występowania LOH w różnych regionach chromosomów w PTC, na podstawie danych z piśmiennictwa [31–33, 
46, 47, 57, 64, 67–69]
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mally deleted region, characteristic for the Hurthle cell 
derived carcinoma (regarded as more aggressive than 
FTC) was identified [58]. It should also be emphasised 
that in anaplastic thyroid carcinoma, a high percentage 
of LOH is found in various chromosomal regions [46, 60, 
73–75]. Results of these reports suggest that LOH may 
be regarded as a late event in thyroid tumourigenesis, 
associated with the loss of tumour differentiation and 
increased degree of aggressiveness.
Some reports have suggested a hypothesis that LOH 
in a specific chromosomal region occurs selectively for 
a given histopathological type of thyroid carcinoma. 
Allelic deletions in 22q have been found to be more 
frequent in highly invasive FTCs with poor prognosis 
[76]. The author of that study did not find LOH in this 
region in case of PTCs, thus suggesting the usefulness 
of LOH analysis in 22q as a prognostic marker specific 
only for FTC. This hypothesis has, however, proved 
controversial, as other researchers have indicated LOH 
in this chromosomal region in various histopathologi-
cal types of thyroid carcinoma, i.e. PTC, FTC and ATC, 
suggesting a participation of deletions in the 22q region 
as a key genetic factor in their development [69, 74]. 
Additionally, LOH within that region was associated 
with the mortality of patients in whom mainly PTC was 
diagnosed [69]. On the other hand, it has been accepted 
that LOH in the 3p25-26 locus (VHL) can be a good prog-
nostic marker for patients with FTC and HTC, due to its 
association with tumour metastases, neoplastic disease 
recurrence and the mortality of patients [65].
Many reports analysing LOH as a prognostic factor 
of neoplastic disease, have pointed to the fact of simulta-
neous loss of heterozygosity in many chromosomal loci.
This observation seems fairly plausible, taking into 
account that carcinogenesis is a multistep process and 
its biologic potential is unlikely to be unravelled with 
the use of a single genetic marker. In particular, it is 
emphasised that the coexistence of genetic material 
loss within the following chromosomes: 1q, 4p, 7p, 9p, 
9q and 16q is a more frequent feature of tumours in 
patients who have died of PTC [69]. Subsequent studies, 
which considered the consequences of genetic material 
loss on the biological course of multifocal PTC, prove 
a more frequent role of LOH in the following regions: 
1p, 7q21, 17p13, 10q23 and 22q13 in spreading neo-
plastic foci within the gland [68]. A lower value of the 
FAL index (35%) was also demonstrated in DNA from 
patients with neoplastic disease (FTC) in their history, 
in whom neither thyroglobulin levels nor radioiodine 
examination indicated any recurrence of the disease. 
A considerably higher FAL index was observed not only 
in patients with documented distant metastases (78%), 
but also in those who died from FTC (67%) [77]. These 
observations may point to LOH coincidence in various 
chromosomal regions, leading to the development of 
aggressive forms of thyroid carcinoma and reflecting 
the clinical progression of neoplasm.
So far, only a few publications have reported a co-
incidence of LOH and/or MSI with a patient’s age as 
a prognostic factor. On the one hand, there is a tendency 
towards more frequent allelic losses in tumours from 
older patients (> 45 years) with PTC [46], which is 
particularly important, as the risk of disease recurrence 
demonstrates a linear growth after the age of 45–50  [78]. 
It is also postulated that an increased incidence of LOH 
may contribute to clinical aggressiveness of carcinoma 
in these patients [46]. However, there are also publica-
tions which have either reported a tendency towards 
more frequent occurrence of LOH/MSI in tumours from 
patients aged below 45 [30] or indicated a lack of any 
association between LOH/MSI and age [32, 33].
A prognosis in the course of PTC may also vary, de-
pending on its histopathological variants. LOH analysis 
in multiple regions (1p34-36, 3p24-26, 3p12-24, 7p31, 
9p21, 10q23, 17p13, 17q21, 18q21, 21q22 and 22q13), 
performed within PTC, demonstrated that LOH coin-
cidence in the loci of 3p24, 9p21, 17q21 and 21q22 might 
reflect a worse prognosis of disease course, particularly 
in the case of the diffuse sclerosis variant of PTC vs. the 
classical or follicular variant of PTC [68]. The observation 
of increasing LOH incidence (expressed as FAL index 
values), reflecting a worse prognosis, has also been 
confirmed in the oncocytic or tall-cell variant of PTC 
[70]. Very few publications have reported a correlation 
between the coexistence of BRAF mutation and LOH in 
1p36, 18q21 and 22q13 and tumour size as a prognostic 
factor: they were significantly higher in PTC > 1 cm 
than in PTC ≤ 1 cm. The authors concluded that these 
genetic lesions might play some role in the faster growth 
of PTC [68]. Similarly, the frequency of allelic loss was 
statistically associated with tumour size > 4 cm, show-
ing an average FAL of 30% and tumours < 4 cm with 
an average FAL of 11% [70].
In turn, the simultaneous loss of heterozygosity in 
10q23, 17p13, 17q21 and 22q13 suggests an association 
of LOH in these loci with PTC metastases into lymph 
nodes [68]. Such an observation may be a hint to ex-
tend studies to search for markers differentiating the 
histopathological variants of PTC, or for prognostic 
markers of disease course.
Summary
Loss of heterozygosity seems to be a more frequent 
phenomenon than MSI, inducing genetic instabil-
ity in thyroid neoplasms in many chromosomal 
regions. MSI may be causatively associated with the 
initiation of molecular changes only, which may later 
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lead to neoplasia, whereas the incidence of LOH 
overtly increases with tumour progression. The inci-
dence of LOH and the numbers of loci, in which the 
loss of heterozygosity occurs, can coexist with muta-
tions (BRAF, RET). This phenomenon increases with 
the degree of neoplastic progression, which indicates 
a successive accumulation of molecular disorders in 
cells and a coincidence of LOH/mutations in thyroid 
tumourigenesis. In the light of the actual studies, 
taking into account the controversial aspects of the 
available data, MSI and/or LOH cannot be regarded 
as informative prognostic markers.
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